Interestingly, diabetic and cardiovascular disease-related RVO patients displayed distinct responses compared to non-diabetic counterparts, with a higher proportion of non-responders to anti-VEGF therapy among diabetics and cardiovascular disease patients. Here, VEGFA is linked to cardiovascular disorder.